132 related articles for article (PubMed ID: 17289902)
1. CD8+ T cells reactive to survivin antigen in patients with multiple myeloma.
Grube M; Moritz S; Obermann EC; Rezvani K; Mackensen A; Andreesen R; Holler E
Clin Cancer Res; 2007 Feb; 13(3):1053-60. PubMed ID: 17289902
[TBL] [Abstract][Full Text] [Related]
2. Full-length dominant-negative survivin for cancer immunotherapy.
Pisarev V; Yu B; Salup R; Sherman S; Altieri DC; Gabrilovich DI
Clin Cancer Res; 2003 Dec; 9(17):6523-33. PubMed ID: 14695157
[TBL] [Abstract][Full Text] [Related]
3. Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity.
Valmori D; Scheibenbogen C; Dutoit V; Nagorsen D; Asemissen AM; Rubio-Godoy V; Rimoldi D; Guillaume P; Romero P; Schadendorf D; Lipp M; Dietrich PY; Thiel E; Cerottini JC; Liénard D; Keilholz U
Cancer Res; 2002 Mar; 62(6):1743-50. PubMed ID: 11912149
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus 16 E6-specific CD45RA+ CCR7+ high avidity CD8+ T cells fail to control tumor growth despite interferon-gamma production in patients with cervical cancer.
Zehbe I; Kaufmann AM; Schmidt M; Hohn H; Maeurer MJ
J Immunother; 2007; 30(5):523-32. PubMed ID: 17589293
[TBL] [Abstract][Full Text] [Related]
5. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
[TBL] [Abstract][Full Text] [Related]
6. Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin.
Piesche M; Hildebrandt Y; Zettl F; Chapuy B; Schmitz M; Wulf G; Trümper L; Schroers R
Hum Immunol; 2007 Jul; 68(7):572-6. PubMed ID: 17584578
[TBL] [Abstract][Full Text] [Related]
7. High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals.
Forsberg O; Carlsson B; Malmström PU; Ullenhag G; Tötterman TH; Essand M
Prostate; 2009 Jan; 69(1):70-81. PubMed ID: 18814178
[TBL] [Abstract][Full Text] [Related]
8. Chemokine C receptor 7 expression and protection of circulating CD8+ T lymphocytes from apoptosis.
Kim JW; Ferris RL; Whiteside TL
Clin Cancer Res; 2005 Nov; 11(21):7901-10. PubMed ID: 16278415
[TBL] [Abstract][Full Text] [Related]
9. Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1.
Maccalli C; Di Cristanziano V; Fodale V; Corsi D; D'Agostino G; Petrangeli V; Laurenti L; Guida S; Mazzocchi A; Arienti F; Perrone MP; Castelli C; Rivoltini L; Zagonel V; Tartaglia M; Parmiani G; Belardelli F
Clin Cancer Res; 2008 Nov; 14(22):7292-303. PubMed ID: 18974390
[TBL] [Abstract][Full Text] [Related]
10. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma.
Neuber B; Herth I; Tolliver C; Schoenland S; Hegenbart U; Hose D; Witzens-Harig M; Ho AD; Goldschmidt H; Klein B; Hundemer M
J Immunol; 2011 Jul; 187(2):1047-56. PubMed ID: 21677134
[TBL] [Abstract][Full Text] [Related]
12. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL.
Dubsky P; Saito H; Leogier M; Dantin C; Connolly JE; Banchereau J; Palucka AK
Eur J Immunol; 2007 Jun; 37(6):1678-90. PubMed ID: 17492620
[TBL] [Abstract][Full Text] [Related]
13. Expression of vascular endothelial growth factor, apoptosis inhibitors (survivin and p16) and CCL27 in alopecia areata before and after diphencyprone treatment: an immunohistochemical study.
Simonetti O; Lucarini G; Bernardini ML; Simoncini C; Biagini G; Offidani A
Br J Dermatol; 2004 May; 150(5):940-8. PubMed ID: 15149507
[TBL] [Abstract][Full Text] [Related]
14. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients.
Andersen MH; Pedersen LO; Becker JC; Straten PT
Cancer Res; 2001 Feb; 61(3):869-72. PubMed ID: 11221872
[TBL] [Abstract][Full Text] [Related]
15. Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma.
Schuberth PC; Jakka G; Jensen SM; Wadle A; Gautschi F; Haley D; Haile S; Mischo A; Held G; Thiel M; Tinguely M; Bifulco CB; Fox BA; Renner C; Petrausch U
Gene Ther; 2013 Apr; 20(4):386-95. PubMed ID: 22739387
[TBL] [Abstract][Full Text] [Related]
16. Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy.
Griffioen M; Kessler JH; Borghi M; van Soest RA; van der Minne CE; Nouta J; van der Burg SH; Medema JP; Schrier PI; Falkenburg JH; Osanto S; Melief CJ
Clin Cancer Res; 2006 May; 12(10):3130-6. PubMed ID: 16707612
[TBL] [Abstract][Full Text] [Related]
17. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.
Idenoue S; Hirohashi Y; Torigoe T; Sato Y; Tamura Y; Hariu H; Yamamoto M; Kurotaki T; Tsuruma T; Asanuma H; Kanaseki T; Ikeda H; Kashiwagi K; Okazaki M; Sasaki K; Sato T; Ohmura T; Hata F; Yamaguchi K; Hirata K; Sato N
Clin Cancer Res; 2005 Feb; 11(4):1474-82. PubMed ID: 15746049
[TBL] [Abstract][Full Text] [Related]
18. Baseline levels of CD8+ T cells against survivin and survivin-2B in the blood of lung cancer patients and cancer-free individuals.
Karanikas V; Soukou F; Kalala F; Kerenidi T; Grammoustianou ES; Gourgoulianis KI; Germenis AE
Clin Immunol; 2008 Nov; 129(2):230-40. PubMed ID: 18789878
[TBL] [Abstract][Full Text] [Related]
19. Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma.
Herth I; Witzens-Harig M; Beckhove P; Hose D; Meissner T; Neuber B; Engelhardt M; Haas J; Neben K; Ho AD; Klein B; Goldschmidt H; Hundemer M
Exp Hematol; 2013 Mar; 41(3):231-40. PubMed ID: 23142220
[TBL] [Abstract][Full Text] [Related]
20. Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vbeta repertoire.
Pérez-Andres M; Almeida J; Martin-Ayuso M; Moro MJ; Martin-Nuñez G; Galende J; Hernandez J; Mateo G; San Miguel JF; Orfao A; ;
Cancer; 2006 Mar; 106(6):1296-305. PubMed ID: 16475149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
